Long noncoding RNAs in intestinal homeostasis, regeneration, and cancer

Yadav, Vipin; Kumar, Amit; Tripathi, Prem Prakash; Gupta, J. R. P.

doi:10.1002/jcp.30393

Cited by 9 publications

(2 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Inflammatory response influences other pathways including Wnt and Hippo pathways via micro-RNA’s and long non coding RNA’s (Inc RNA) important in many cancers’ progression via regulating NK-κB and STAT3 signaling in various cancers. IL-22 produced by neutrophils, Th17 and Th22 and lymphoid cells attempt to express the H19 Inc RNA enhancing the proliferation of colon epithelial cells involved with carcinogenesis (Yadav et al 2021 ).…”

Section: Inflammation Leads To Cancermentioning

confidence: 99%

Nanomedicines: intervention in inflammatory pathways of cancer

Anwar

Naqvi

Shams³

et al. 2023

Inflammopharmacol

View full text Add to dashboard Cite

Inflammation is a complex defense process that maintains tissue homeostasis. However, this complex cascade, if lasts long, may contribute to pathogenesis of several diseases. Chronic inflammation has been exhaustively studied in the last few decades, for its contribution in development and progression of cancer. The intrinsic limitations of conventional anti-inflammatory and anti-cancer therapies triggered the development of nanomedicines for more effective and safer therapies. Targeting inflammation and tumor cells by nanoparticles, encapsulated with active therapeutic agents, offers a promising outcome with patient survival. Considerable technological success has been achieved in this field through exploitation of tumor microenvironment, and recognition of molecules overexpressed on endothelial cells or macrophages, through enhanced vascular permeability, or by rendering biomimetic approach to nanoparticles. This review focusses on the inflammatory pathways in progression of a tumor, and advancement in nanotechnologies targeting these pathways. We also aim to identify the gaps that hinder the successful clinical translation of nanotherapeutics with further clinical studies that will allow oncologist to precisely identify the patients who may be benefited from nanotherapy at time when promotion or progression of tumor initiates. It is postulated that the nanomedicines, in near future, will shift the paradigm of cancer treatment and improve patient survival. Graphical abstract

show abstract

Section: Inflammation Leads To Cancermentioning

confidence: 99%

Nanomedicines: intervention in inflammatory pathways of cancer

Anwar

Naqvi

Shams³

et al. 2023

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

“…Traditionally, somatic mutations in protein-coding genes were thought as the driving force of cancer development and occurrence. Nevertheless, over the past decade, some gaps in the knowledge of the genomic complexity have been filled by the identification of several families of long RNAs [ 3 , 4 ]. In particular, massive parallel sequencing technology has revealed that noncoding regions of the human genome are also dysregulated in various types of cancer [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA HEIH: a novel tumor activator in multiple cancers

Sun

2021

Cancer Cell Int

View full text Add to dashboard Cite

The last decade has witnessed the altered expression levels of long non-coding RNA HEIH in different types of cancer. More than half of the HEIH studies in cancer have been published within the last two years. To our knowledge, this is the first review to discuss very recent developments and insights into HEIH contribution to carcinogenesis. The functional role, molecular mechanism, and clinical significance of HEIH in human cancers are described in detail. The expression of HEIH is elevated in a broad spectrum of cancers, and its disorder contributes to cell proliferation, migration, invasion, and drug resistance of cancer cells through different underlying mechanisms. In addition, the high expression of HEIH is significantly associated with advanced tumor stage, tumor size and decreased overall survival, suggesting HEIH may function as a prognostic biomarker and potential therapeutic target for human cancers.

show abstract

Exploring the relationship between immune heterogeneity characteristic genes of rheumatoid arthritis and acute myeloid leukemia

Jiang,

Liu

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Background People with autoimmune diseases are prone to cancer, and there is a close relationship between rheumatoid arthritis (RA) and acute myeloid leukemia (AML). The bone marrow (BM) is affected throughout the course of RA, with a variety of hematologic involvement. Hopes are pinned on rheumatoid arthritis research to obtain BM biomarkers for AML. Methods Synovial transcriptome sequencing data for RA and osteoarthritis (OA), and single-cell sequencing data for RA and controls were obtained from the GEO database.Bone marrow sequencing data for AML patients and normal subjects were obtained from the UCSC Xena database. The final immune heterogeneity characteristics of RA were determined through ssGSEA analysis, gene differential expression analysis, fuzzy c-means clustering algorithm, and XGboost algorithm. Random Ferns classifiers (RFs) are used to identify new bone marrow markers for AML. Results SELL, PTPRC, IL7R, CCR7, and KLRB1 were able to distinguish leukemia cells from normal cells well, with AUC values higher than 0.970. Conclusion Genes characterizing the immune heterogeneity of RA are associated with AML, and KLRBA may be a potential target for AML treatment.

show abstract

Long noncoding RNAs in intestinal homeostasis, regeneration, and cancer

Cited by 9 publications

References 115 publications

Nanomedicines: intervention in inflammatory pathways of cancer

Nanomedicines: intervention in inflammatory pathways of cancer

Long non-coding RNA HEIH: a novel tumor activator in multiple cancers

Exploring the relationship between immune heterogeneity characteristic genes of rheumatoid arthritis and acute myeloid leukemia

Contact Info

Product

Resources

About